70
Participants
Start Date
December 1, 2025
Primary Completion Date
October 1, 2028
Study Completion Date
October 1, 2030
Niraparib
Niraparib will be administered orally (PO) daily as tablets at one of three possible dose levels, 100mg/day, 200mg/day or 300mg/day, based upon participant weight, platelet count, and certain drug combinations and conditions assessed at baseline.
RECRUITING
University of Miami, Miami
Collaborators (1)
GlaxoSmithKline
INDUSTRY
University of Miami
OTHER